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ABSTRACT: The advent of the human immunodeficiency virus infection and the increasing prevalence of compromised
individuals in the community due to modern therapeutic advances have resulted in a resurgence of opportunistic infections,
including oral candidoses. One form of the latter presents classically as a white lesion of "thrush" and is usually easily diag-
nosed and cured. Nonetheless, a minority of these lesions appears in new guises such as erythematous candidosis, there-
by confounding the unwary clinician and complicating its management. Despite the availability of several effective antimy-
cotics for the treatment of oral candidoses, failure of therapy is not uncommon due to the unique environment of the oral
cavity, where the flushing effect of saliva and the cleansing action of the oral musculature tend to reduce the drug concen-
tration to sub-therapeutic levels. This problem has been partly circumvented by the introduction of the triazole agents,
which initially appeared to be highly effective. However, an alarming increase of organisms resistant to the triazoles has
been reported recently. In this review, an overview of clinical manifestations of oral candidoses and recent advances in
antimycotic therapy is given, together with newer concepts, such as the post-antifungal effect (PAFE) and its possible thera-
peutic implications.
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(I) Introduction
Candidosis is by far the most common oral fungal
infection in man and manifests in a variety of clini-
cal guises. The main reason for the high incidence of
oral candidosis in man appears to be the multiplicity of
predisposing factors which aid and abet the conversion
of commensal Candida to a parasitic existence. For
instance, it is known that, in the West, a majority of
elderly denture-wearers suffer from Candida-associated
denture stomatitis by virtue of the prostheses being
constantly worn in the mouth (Budtz-Jorgensen et al.,
1975; Samaranayake, 1990; Kuc et al., 1999). Further, the
advent of the human immunodeficiency virus (HIV)
infection has resulted in a resurgence of oral candidal
infections. Thus, it has been reported that more than
90% of HIV-infected individuals develop oral candidosis
during some point of their disease; it is by far the most
common oral manifestation in these patients
(Samaranayake and Holmstrup, 1989; Feigal et al., 1991;
Arendorf et al., 1998). The existence of these individuals,
together with other compromised patient groups in the
community, along with the usage of broad-spectrum
antibiotics and corticosteroids, and common endocrine
disorders such as diabetes mellitus-all have resulted
in a resurgence of oral candidosis as a relatively com-
mon affliction (Samaranayake, 1990).
Yeasts which belong to the genus Candida are
imperfect unicellular dimorphic fungi which multiply,
primarily, by the production of buds from ovoid blas-
tospores or blastoconidia; they also form hyphae
and/or pseudohyphae, depending on environmental
conditions (Fig. 1). In general, from 50 to 60% of
humans carry Candida in the oral cavity (Samaranayake
and Lamey, 1988), although there may be some geo-
graphic variations (Sedgley et al., 1997).
C. albicans is the most common Candida species resid-
ing in the oral cavity, in both health and disease, and is
the agent of most oral candidal infections
(Samaranayake and MacFarlane, 1990; Zegarelli, 1993;
Silverman et al., 1996). All forms of oral candidoses are
considered opportunistic, and hence the epithet "the dis-
ease of the diseased" given to this condition
(Samaranayake and MacFarlane, 1990). Perusal of recent
literature reveals that oral manifestations of candidal
infections could be many and varied. These range from
erythematous variants, linear gingival erythema associ-
ated with HIV infection, to median rhomboid glossitis,
possibly of multi-factorial origin. In this review, we
attempt to describe these entities, in some depth,
together with approaches to management, especially in
relation to antifungal therapy.
Several effective antifungal agents are available for
the management of oral candidosis (Garber, 1994;
Greenspan, 1994), and they are administered either top-
ically or systemically. These agents range from the clas-
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sic polyenes to the azole groups. Newer
antifungal agents which are in the experi-
mental and trial stages include
amorolfine, natifine, terbinafine, tolaftate
(McGinnis and Rinaldi, 1996), rilopirox
(Braga el, 1996), cilofungin, pradimycin
(Samaranayake and Ferguson, 1994),
voriconazole (Ruhnke et al, 1997), and
benanomicin A (Ohtsuka et cil., 1997).
These will not be discussed in detail in
this review.
Despite the availability of such a
multiplicity of agents, therapeutic failure
is not uncommon (Samaranayake and
MacFarlane, 1981). In general, treatment
of fungal infections is considerably more
difficult than treatment of bacterial infec-
tions. Many fungal infections occur in the
poorly vascularized tissues or avascular
structures such as the superficial layer of
the mucosae, skin, nails, and hair.
Management of these poses a therapeu- aindurheypha ca
tic problem due to the poor solubility,
distribution, and retention of adequate amounts of
some of these drugs at the site of infection (Finch and
Snyder, 1994) In the case of the mouth, the diluent
effect of saliva and the cleansing action of the oral mus-
culature, in particular the tongue, often tend to reduce
the availability of the antifungal agents below the effec-
tive therapeutic concentrations (Martin, 1989, 1990).
Further, Candida biofilms on oral and inert surfaces such
as prostheses may also contribute to failure of drug
therapy (Hawser and Douglas, 1995). Finally, poor
patient compliance due to the need for frequent drug
administration and associated adverse effects, coupled
with a possible underlying immunodeficiency, can also
impair therapy, resulting in chronic recurrence of the
disease.
What follows is a description of the clinical manifes-
tations of oral candidosis together with common thera-
peutic agents that are used in the management of oral
candidosis. In addition, susceptibility testing of antimy-
cotics and newer concepts such as the post-antifungal
effect (PAFE) and their impact on the management of
oral candidosis will be addressed
(11) Candida
and Clinical Manifestations
of Oral Candida Infections
The fungal infections of the oral mucosa most frequently
encountered are those due to species of the genus
Candida, and C. albicans is the principal species associated
with this infection (Samaranayake and MacFarlane, 1990),
but non-albicans species such as tropicalis, glabratci, parapsilo-
nning electron micrograph illustrating blastospores, budding yeast cells,
o C. albicans attached to buccal epithelial cells.
sis, and krusei are also pathogenic to man The latter three
species are considered emerging pathogens and are
reviewed in detail elsewhere (Weems, 1992;
Samaranayake and Samaranayake, 1994. Fidel et al, 1999)
C dubliniensis is a recently described species associated
with oral lesions in HIV-infected individuals and is close-
ly related to C. albicans, both phenotypically and genotypi-
cally (Sullivan et al, 1995)
Candida is present as a commensal in the oral cavi-
ties of up to 40% of healthy individuals. The number of
organisms in the saliva of carriers increases in pregnan-
cy, with tobacco smoking, and when dentures are worn
(Samaranayake, 1996). The primary oral reservoir for the
organism in carriers is the dorsum of the tongue, where
it is usually found as blastospores There is an overlap in
the candidal counts from carriers and from individuals
showing infection, and hence isolation of Candida from
the mouth of an adult is not confirmatory evidence of
infection and must be considered in tandem with the
clinical findings (Samaranayake and MacFarlane, 1990,
Soames and Southam, 1993).
Candida species are notorious opportunistic
pathogens (Odds, 1994), and both general and local pre-
disposing factors are important in the pathogenesis of
oral candidal infections. For instance, debilitated
patients such as those receiving broad-spectrum anti-
biotics, steroids, or cytotoxic therapy, patients with dia-
betes mellitus, xerostomia, severe nutritional deficien-
cies, and immunosuppressive diseases such as AIDS are
more prone to oral candidosis (Samaranayake, 1991).
Further local factors, such as trauma from unhygienic or
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TABLE 1
Classification of Oral Candidosis[as Proposed by Samaranaoake (1991)
and Modified by Axell et a. (1997)]
Primary Oral Candidoses Secondary Oral Candidoses
Acute forms Oral manifestations of sys-
Pseudomembranous temic mucocutaneous candi-
Erythematous dosis as a result of diseases
Chronic forms such as a thymic aplasia
Hyperplastic and candidosis
Nodular endocrinopathy syndrome
Plaque-like
Erythematous
Pseudomembranous
Candidc-associated lesions
Denture stomatitis
Angular cheilitis
Median rhomboid glossitis
Keratinized primary lesions superinfected with Candida
Leukoplakia
Lichen planus
Lupus erythematosus
* Note: Candida may also contribute to the development of linear
gingival erythema (LGE) and necrotizing periodontal disease in
HIV infection.
ill-fitting dentures and tobacco smoking, are also impor-
tant (Scully et al., 1994). Nevertheless, it is often difficult
to identify the exact predisposing factor, despite inten-
sive investigation (Samaranayake and Lamey, 1988).
Classification of oral Candida infections is fraught
with difficulties due to the varied manifestations of the
disease. It is generally accepted that oral candidosis can
be divided into two broad categories, i.e., primary and
secondary oral candidosis (Samaranayake and Yaacob,
1990; Table 1). Thus, candidal infections confined to oral
and peri-oral tissues are considered primary oral candi-
doses, and disorders where oral candidosis is a manifes-
tation of generalized systemic candidal infections are cat-
egorized as secondary oral candidosis (Samaranayake,
1996; Axell et al., 1997). The primary oral candidoses are
subclassified into three major variants, viz.: pseudomem-
branous, erythematous, and hyperplastic, each of which
may manifest as acute or chronic lesions. The essential
difference between the newer and the old classifications
is that the former attempts to define the lesions more in
terms of clinical rather than histopathologic criteria
(Axell et al., 1997). Despite such attempts at drawing a
distinction between disease variants, there are condi-
tions-such as cheilo-candidosis and chronic multifo-
cal candidosis-which do not fall strictly into any of
these categories. The former presents as a chronic,
ulcerative granulating lesion of the vermilion area of the
lower lip, while the latter causes chronic, erythematous
plaque-like lesions in two or more sites in either the
mouth, palate, or dorsum of the tongue (Samaranayake
and Lamey, 1988).
Candida and oral candidosis have been previously
reviewed elsewhere (Samaranayake and MacFarlane,
1990; Odds, 1994; Scully et al., 1994). Discussed below is
a brief account of the variants of oral candidosis.
(A) PSEUDOMEMBRANOUS CANDIDOSIS
Classically, this is an acute infection, but it may recur
for many months or even years in patients using corti-
costeroids topically or by aerosol, and in immunocom-
promised patients. It may also be seen in neonates and
among terminally ill patients, particularly in associa-
tion with serious underlying conditions such as
leukemia and other malignancies, and is increasingly
seen in HIV disease.
Thrush is characterized by white patches on the sur-
faces of the oral mucosa, tongue, and elsewhere. The
lesions form confluent plaques that resemble milk curd
and can be wiped off to reveal a raw, erythematous, and
sometimes bleeding base (Samaranayake, 1996).
Esophageal candidosis, or candidosis of the upper
respiratory tract, is a possible complication of oro-pha-
ryngeal candidosis. The combination of oral and
esophageal candidosis is particularly common in HIV
infection.
(B) ERYTHEMATOUS CANDIDOSIS
Previously known as antibiotic sore mouth, and the
atrophic variant, erythematous candidosis is associated
with chronic usage of corticosteroids, broad-spectrum
antibiotics, and, more commonly, with HIV disease. It
may arise as a consequence of persistent acute
pseudomembranous candidosis, when pseudomem-
branes are shed, may develop de novo, or, in HIV infection,
may precede pseudomembranous candidosis. It is the
most common variant of candidosis seen in HIV disease
(Samaranayake and Holmstrup, 1989).
Clinically, erythematous areas are seen on the dor-
sum of the tongue, palate, or buccal mucosa. Lesions on
the dorsum of the tongue present as depapillated areas.
Red areas often seen in the palate in HIV disease are
thought to be due to reduced epithelial thickness and/or
increased vascularity. There can be an associated angular
stomatitis.
(C) HYPERPLASTIC CANDIDOSIS
(CANDIDA LEUKOPLAKIA)
Candida leukoplakias are chronic, discrete raised lesions
that vary from small, palpable, translucent, whitish
areas to large, dense, opaque plaques, hard and rough
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on palpation (plaque-like lesions). They may present as
homogenous or speckled lesions (nodular lesions)
which do not rub off. Candida leukoplakias usually occur
on the inside surface of one or both cheeks at the com-
missural areas and less often on the tongue. Since the
condition is pre-malignant and shows various degrees
of dysplasia, biopsy is important. The risk of malignant
transformation in candidal leukoplakia (approximately
15%) depends on whether the lesion is homogenous or
speckled, the presence and degree of epithelial dyspla-
sia, and the management adopted (Walker and Arendorf,
1990). Iron and folate deficiency and defective cell-medi-
ated immunity have been associated with Candida leuko-
plakias in a few cases.
In addition to the foregoing three major variants of
oral candidosis, there are several other lesions associat-
ed with Candida infection, as described below.
(D) Candida-AssOCLkTED DENTURE STOMATITIS
(DENTURE-INDUCED STOMATITIS, DENTURE SORE
MOUTH, CHRONIC ATROPHIC CANDIDOSIS)
The characteristic presenting features of denture-
induced stomatitis are chronic erythema and edema of
the mucosa that comes into contact with the fitting sur-
face of the denture; this condition is mainly due to the
overgrowth of commensal strains of C. albicans beneath
the dentures (Mathaba et al., 1995). The mucosa
beneath the mandibular dentures is hardly ever
involved. Apart from soreness, this condition is usually
symptomless. The only presenting complaint may be
an associated angular stomatitis. A few patients have
complained of a burning or tingling sensation beneath
the denture.
Denture-induced stomatitis has been classified
into three clinical types: type I, a localized simple
inflammation or a pinpoint hyperemia; type 11, an ery-
thematous or generalized simple type presenting as
more diffuse erythema involving a part of, or the entire,
denture-covered mucosa; and type III, a granular or
papillary type commonly involving the central part of
the hard palate and alveolar ridge (Newton, 1962). It
was thought that the papillary types of lesions are
essentially due to the presence of the prostheses.
However, a recent report of similar lesions in HIV infec-
tion implies that the denture is not the prime etiologic
factor for the condition (Reichart et al., 1997).
The presence of dentures can also cause changes in
the microbial flora and accumulation of plaque between
the mucosal surface of the denture and the palate. Thus,
denture-induced stomatitis is most often caused by the
accumulation of microbial plaque on and in the fitting
surface of the denture and the underlying mucosa. It is
not exclusively associated with Candida. Other factors-
such as bacterial infection, mechanical irritation, or an
allergic reaction to the denture base material-have
also been implicated (Budtz-l0rgensen, 1990).
(E) ANGULAR STOMATITIS
(PERLECHE, ANGULAR CHEILITIS)
Angular stomatitis affects the angles of the mouth, char-
acterized by soreness, erythema, and fissuring, and is
commonly associated with denture-induced stomatitis
(Budtz-l0rgensen, 1990). Both yeasts and bacteria (espe-
cially Staphylococcus aureus) are involved, as interacting
and predisposing factors (Budtz-J0rgensen, 1990;
Warnakulasuriya et al., 1991; Dias and Samaranayake,
1995). Angular stomatitis may present as an isolated fea-
ture of iron deficiency anemia or vitamin B12 deficiency,
which may resolve once the underlying disease has been
treated. It may also be seen in patients with HIV disease
(Samaranayake and Holmstrup, 1989). It is likely that the
lesion is a result of skin maceration at deep, occlusive
folds of the skin at the angles of the mouth in individu-
als with reduced facial height caused by old age or ill-fit-
ting dentures.
Exfoliative chelitis, predominantly of the lower lip,
may be associated with Candida, especially in HIV infec-
tion, and could be considered another variant of candi-
dosis in AIDS patients (Reichart et al., 1997).
(F) MEDIAN RHOMBOID GLOSSITIS
Median rhomboid glossitis is characterized by an area of
papillary atrophy that is elliptical or rhomboid, symmet-
rically placed at the midline of the tongue, anterior to the
circumvallate papillae. Occasionally, it presents with a
hyperplastic exophytic or even lobulated appearance.
The relevance of Candida to the etiology of the condition
has been controversial (Walker and Arendorf, 1990). A
mixed bacterial and fungal flora may be associated with
the condition (Scully et al., 1994).
(G) CHRONIC MULTIFOCAL ORAL CANDIDOSIS
This term has been given to chronic candidal infection
that may be seen in multiple oral sites, with various
combinations, including: (1) angular stomatitis, which is
unilateral or bilateral and associated with denture wear-
ers; (2) retro-commissural leukoplakia; (3) median
rhomboid glossitis; and (4) palatal lesions. Additional
criteria may include: (1) lesions of more than four weeks'
duration; (2) an absence of predisposing medical condi-
tions; and (3) exclusion of patients who had received
radiotherapy or any of the following drugs: antibiotics,
anti-inflammatory or immunosuppressive drugs, and
cytotoxic or psychotropic agents (Holmstrup and
Bessermann, 1983).
At the time of presentation, most patients are adult
male tobacco-smokers, in their fifth or sixth decade.
Though antifungal therapy would clear the infection and
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produce clinical improvement, recurrence is common,
unless smoking can be reduced.
(H) ORAL CANDIDOSIS ASSOCIATED
WITH SYSTEMIC INFECTIONS
Candidosis is usually restricted to the skin and
mucous membranes but may occasionally spread.
Systemic forms of candidosis may affect only one
organ or be disseminated hematogenously (Odds,
1994). It is important to recognize that oral candidal
infections can also manifest as a result of such sys-
temic disease. However, most of these complications,
with the exception of acquired immunodeficiency syn-
drome (AIDS), are rare; the candidosis remains super-
ficial, and patients usually do not die from dissemi-
nated candidosis. Interestingly, a case of Candida-asso-
ciated zygomatic osteomyelitis has been reported in a
diabetic patient with oral candidosis (Arranz-Caso et
al., 1996).
(I) CANDIDOSIS
AND THE IMMUNOCOMPROMISED HOST
A few patients have chronic candidosis from an early
age, sometimes with a definable and heritable immune
defect (e.g., chronic mucocutaneous candidosis).
However, the number of patients immunocompromised
by disease such as HIV infection, by hematological
malignancy, and by drug therapies such as aggressive
cytotoxic therapy has increased during recent years and
constitutes by far the largest immunocompromised
group in the community.
(a) Chronic mucocutaneous candidosis (CMC)
CMC is the term given to the group of rare syndromes,
sometimes with a definable immune defect, in which there
is a persistent mucocutaneous candidosis that responds
poorly to topical antifungal treatment (Kirkpatrick, 1993).
In general, the more severe the candidosis, the greater the
likelihood that immunological defects can be identified.
Recent studies suggest that a defect in cytokine (inter-
leukin-2 and gamma interferon) production in response to
candidal and some bacterial antigens, along with reduced
serum levels of IgG2 and IgG4, may be a major cause for
the infection (Lilic et al., 1996).
(b) HIV-related oral candidosis
Ever since the first clinical definition of AIDS in 1981, the
CDCAWHO have recognized candidosis of the mouth as
one of the major opportunistic infections and an impor-
tant indicator of HIV infection. For instance, more than
90% of HIV-infected patients suffer from oral candidosis
at some point in the course of the disease
(Samaranayake and Holmstrup, 1989; Feigal et al., 1991;
Greenspan, 1994), and it is by far the most common fun-
gal infection in HIV disease (Begg et al., 1996; Arendorf et
al., 1998). Oral carriage of Candida species is also
increased in these patients (Scheutz et al., 1997). Further,
immunocompromised persons are also at particular risk
from deep mycoses which may cause chronic oral ulcer-
ation, bizarre mouth lesions, or maxillary sinus infection
(Scully et al., 1997).
The main cause of oral candidosis in HIV infection is
immune impairment. However, Candida itself may also
induce immunosuppression, and this can influence the
prognosis of HIV infection (Odds, 1994).
The manifestations of candidal infections in HIV infec-
tion are usually restricted to superficial candidosis with var-
ious degrees of severity. The major clinical variants of oral
candidosis-namely, pseudomembranous, erythematous,
and hyperplastic candidoses-have all been described in
HIV-infected individuals (Kolokotronis et al., 1994; Silverman
et al., 1996). Pseudomembranous candidosis may involve
any area of the oral mucosa, but most frequently the tongue,
hard and soft palate, and buccal mucosa.
The erythematous form of candidosis may be a com-
mon early oral manifestation of HIV infection and pre-
sents as a pink or red macular lesion, typically on the
palate and dorsum of the tongue, often mixed with white
lesions (Kolokotronis et al., 1994; Silverman et al., 1996).
Papillary hyperplasia is occasionally seen in the palate
(Reichart et al., 1994).
Candida may also contribute to the development of
linear gingival erythema (LGE) or necrotizing periodontal
diseases in HIV-infected persons (Odden et al., 1994;
Grbic et al., 1995).
(111) Treatment of Oral Candidosis
Antifungal agents that are available for the treatment of
candidosis fall into three main categories: the polyenes
(nystatin and amphotericin B); the ergosterol biosynthe-
sis inhibitors - the azoles (miconazole, clotrimazole,
ketoconazole, itraconazole, and fluconazole), allyl-
amines, thiocarbamates, and morpholines; and the DNA
analogue 5-fluorocytosine (White et al., 1998). The histor-
ical development and introduction of these agents for
therapeutic use over the last half century are summa-
rized in Table 2 (Sheehan et al., 1999). However, the prin-
cipal antifungals used against oral mycoses belong to
the polyenes and the azoles (Epstein, 1990;
Samaranayake, 1996; Table 3).
(A) POLYENE ANTIFUNGAL AGENTS
Two polyenes-namely, amphotericin B and nystatin-
are commonly used for the treatment of oral candidosis.
Though fungal resistance to these agents is rare/low
(McGinnis and Rinaldi, 1996; White et al., 1998), signifi-
cant resistance in yeasts, including C. albicans, has been
176 Crit Rev Oral Bid Med 1 1(2):172-198Crit Rev Oral Biol Med 11(2):172-198 (2000)
TABLE 2
Key Events in Antifungal Drug Development (Sheehan et al., 1999)
1940's 1950's 1960's 1970's 1980's 1990's
1944 1956 1960 1974 1981 1990-92
First antifungal Amphotericin B Amphotericin B Econazole intro- Ketoconazole oral First systemic tria-
azole reported antifungal activity introduced duced formulation zoles fluconazole
reported approved in US and itraconazole
introduced in US
1949 1958 1962 1979 1981 1995-96
First polyene nys- First azole antifun- Flucytosine Miconazole par- First allylamine Second allylamine
tatin identified gal marketed antifungal activity enteral formulation natifine* in clinical terbinafine*
reported introduced in UK trials approved and
amphotericin B
lipid formulations
approved
1969 1987 1997
Miconazole and Polyene lipid for- Itraconazole oral
clotrimazole (topi- mulations in devel- solution approved
cal) introduced opment
* Trials are under way. Not discussed in text.
reported in isolates from cancer patients with prolonged ease in man, including Candida spp.
neutropenia (Lambert and O'Grady, 1992). Amphotericin B is poorly absorbed from the intesti-
nal tract and is usually administered intravenously or
(a) Amphotericin B topically. After an intravenous injection, the drug is
This agent acts by inhibiting fungi through an interaction rapidly sequestered in tissues and then is slowly
with ergosterol (a fungal membrane sterol). This effect released, with an initial half-life of 1-2 days followed by a
results in the loss of membrane-selective permeability slow elimination phase of about 15 days. It is highly pro-
and intracellular components, which in turn causes tein-bound in serum, and this characteristic may partly
impairment of barrier functions, leakage of cellular com- account for its poor penetration into many body sites,
ponents, and cell death. Depending on the concentration including the CSF, the urine, and the chambers of the
used, amphotericin B will exert either a fungistatic or a eye. The major route of its excretion is extra-renal
fungicidal effect. At low concentrations, leakage of cell (Lambert and O'Grady, 1992; Finch and Snyder, 1994).
constituents is restricted to small molecules and ions Since this antimycotic is a broad-spectrum agent
(sodium and potassium), and the damage is reparable. that is active against yeast and yeast-like as well as
However, a paradoxical stimulatory effect of ampho- dimorphic and filamentous fungi, it is the drug of choice
tericin B, which results in an increase in the number of in most systemic mycoses. However, the duration of
colony-forming units of C. albicans. has also been report- treatment will depend upon the severity of fungal infec-
ed (Brajtburg et al., 1981). At high concentrations of the tion as well as the intensity of underlying illness, as in
drug, larger molecules are transported through the mem- the case of HIV infection.
brane, producing irreversible loss of cell constituents Though not very popular, topical amphotericin B oral
and its subsequent disruption. Since mammalian cell preparations (lozenges, mouthwashes, creams, oint-
membrane also contains sterols, this drug accounts for a ments) are available for the treatment of oral candidosis.
certain degree of host toxicity. However, the polyenes While topical therapy may be useful in its own right in
bind more effectively to ergosterol, the principal sterol in primary oral candidosis, it could be used as an adjunct to
fungal membranes, than to other mammalian sterols parenteral therapy in secondary candidosis, which mani-
such as cholesterol (Warnock, 1991; Lambert and fests both systemically as well as on mucosal surfaces.
O'Grady, 1992; Finch and Snyder, 1994; Lesse, 1995). Its Apart from the fungicidal effect, amphotericin B is
spectrum of activity includes most fungi that cause dis- capable of suppressing many pathogenic attributes of C.
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TABLE 3
Antifungal Agents Used in the Treatment of Oral Candidoses (from various sources)
Drug Form Dosage Comments
Amphotericin B Lozenge, 10 mg
Oral suspension,
1 00 mg/mL
Slowly dissolved in mouth
3-4 X/day after meals
for 2 wks minimum.
Placed in the mouth after
food and retained near
lesions 4X/day for 2 wks.
Negligible absorption from gastrointestinal tract. When given IV for deep
mycoses may cause thrombophlebitis, anorexia, nausea, vomiting,
fever, headache, weight loss, anemia, hypokalemia, nephrotoxicity,
hypotension, arrhythmias, etc.
Cream Apply to affected area
3-4 X/day.
Pastille, 100,000 units Dissolve 1 pastille slowly
after meals 4X/day,
usually for 7 days.
Oral suspension, Apply after meals 4X/day,
100,000 units usually for 7 days, and
continue use for several
days after post-clinical
healing.
Negligible absorption from gastrointestinal tract. Nausea and
vomiting with high doses.
Clotrimazole Cream
Solution
Miconazole Oral gel
Cream
Ketoconazole Tablets
Fluconazole Capsules
Itraconazole Capsules
Apply to the affected
area 2-3 times daily for
3-4 wks.
5 mL 3-4 times daily for
2 wks minimum.
Apply to the affected area
3-4 times daily.
Apply twice per day and
continue for 10-14 days
after the lesion heals.
200-400-mg tablets taken
once or twice daily with
food for 2 wks.
50-1 00-mg capsule once
daily for 2-3 wks.
100-mg capsules daily
taken immediately after
meals for 2 wks.
Mild local effects. Also has anti-staphylococcal activity.
Occasional mild local reactions. Also has antibacterial activity.
Theoretically the best antifungal to treat angular cheilitis. Interacts
with anticoagulants (warfarin), terfenadine, cisapride, and astemi-
zole. Avoid in pregnancy and porphyria.
May cause nausea, vomiting, rashes, pruritus, and liver damage.
Interacts with anticoagulants, terfenadine, cisapride, and
astemizole. Contraindicated in pregnancy and liver disease.
Interacts with anticoagulants, terfenadine, cisapride, and astemizole.
Contraindicated in pregnancy, liver and renal disease. May cause
nausea, diarrhea, headache, rash, liver dysfunction.
Interacts with terfenadine, cisapride, and astemizole. Contraindicated
in pregnancy and liver disease. May cause nausea, neuropathy, rash.
albicans at lower concentrations. For instance, it suppresses
adhesion of C. albicans to buccal epithelial cells (Brenciaglia
et al., 1986; Macura, 1988; Vuddhakul et al., 1988; Abu-El
Teen et al., 1989), and inhibits their germ tube formation
(Brenciaglia et al., 1986; Abu-El Teen et al., 1989). On the
other hand, amphotericin B pre-exposed denture acrylic
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Nystatin
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suppresses candidal adhesion to a significant extent
(McCourtie et al., 1986). The former effects may be due to
the mechanism of action of amphotericin B on the candidal
cell wall, while the latter may be due to the blocking of the
yeast attachment sites on the denture acrylic by the drug.
Candida is also well-known to produce enzymes, such
as secretory aspartyl proteinases (Saps), which facilitate
both attachment to and penetration of the mucous
membranes (Samaranayake and MacFarlane, 1990).
Interestingly, subminimal inhibitory concentrations
(sub-MIC) of amphotericin B are capable of curtailing the
activity of this enzyme in oral C. albicans isolates (Wu et al.,
1996), thus reducing its pathogenicity. On the contrary,
exposure of C. albicans to sub-MIC of amphotericin B has
resulted in enhanced resistance to apo-lactoferrin-medi-
ated candidal cell death (Nikawa et al., 1994). Apo-lacto-
ferrin is an important antifungal proteinaceous compo-
nent of saliva. Recent literature therefore indicates that
amphotericin B has a multiplicity of effects on Candida,
killing the organism at high concentrations and adverse-
ly modulating the pathogenic attributes of the yeast at
lower concentrations. The effects of sub-therapeutic con-
centrations of antifungal agents, including the post-anti-
fungal effect (PAFE), will be discussed later.
The most common and most serious adverse effect of
systemic amphotericin B is nephrotoxicity (Table 3).
Hypokalemia and mild anemia are also common. Other
rare adverse effects include acute hypersensitivity reactions
such as anaphylaxis, fever, and headache; vomiting, anorex-
ia, backache, seizures, and thrombophlebitis at the site of
injection have also been reported (Lambert and O'Grady,
1992; Finch and Snyder, 1994). Amphotericin B may poten-
tiate nephrotoxicity of other agents such as aminoglyco-
sides and cyclosporin, while concomitant administration of
glucocorticoids may exacerbate electrolyte disturbances,
especially hypokalemia. Synergistic and antagonistic
effects have been reported with other antifungal agents and
amphotericin B. Mechlorethamine and other anticancer
agents may potentiate the nephrotoxic and hypotensive
effects of amphotericin B (Lesse, 1995).
The currently available preparations for oral delivery
of amphotericin B include an ointment, suspensions,
creams, and lozenges. Inhibitory concentrations of
amphotericin B can be detected in saliva up to 2 hrs after
a single lozenge dose (Samaranayake and Ferguson,
1994). The oral dose for adults is 100-200 mg every 6 hrs.
Lozenges (10 mg) can be given every 8 hrs to a maximum
of 80 mg/day. Also, 1 mL of oral suspension (100 mg/mL)
taken after food and retained near the lesion every 8 hrs
is recommended. Intravenous infusions can be adminis-
tered, with care, to adults and children at 0.25 mg/kg
daily, with a maximum of 1.5 mg/kg daily in severely ill
patients (Lambert and O'Grady, 1992).
(b) Nystatin
Nystatin is a polyene antifungal which has a mode of
action identical to that of amphotericin B. It too prevents
the biosynthesis of ergosterol in the fungal cell mem-
brane, which is important for the fluidity and integrity of
the membrane and for the function of many membrane-
bound enzymes, including chitin synthetase, which is
necessary for proper cellular growth and division (White
et al., 1998). Blocking of ergosterol biosynthesis alters the
permeability of the yeast cell membrane, resulting in
leakage of cell constituents and death. Nystatin is prob-
ably the most popular agent for treating superficial fun-
gal infections caused by C. albicans. It has both a fungici-
dal and a fungistatic activity, depending on the concen-
tration administered.
Due to its systemic toxicity, nystatin is used topical-
ly in the treatment of mucocutaneous infections caused
by C. albicans. Pharmaceutical preparations of nystatin
contain a heterogenous mixture of compounds in addi-
tion to the main ingredient, and hence the biological
activity of nystatin is commonly expressed in interna-
tional units (IU) (Samaranayake and Ferguson, 1994).
Nystatin is available in creams, tablets, suspensions,
oral rinses, gels, and pastilles (Lesse, 1995). The ointment
contains perfumes and other agents and is not suitable
for intra-oral use, but has been used for the treatment of
angular cheilitis. Nystatin tablets (500,000 IU) are com-
monly used for the treatment of oral candidosis, as are
unflavored vaginal tablets (100,000 IU). The latter is high-
ly efficacious when used orally as long as the patient is
persuaded to take them; the bitter taste of the tablets,
however, results in poor patient compliance (Greenspan,
1994). The suspension can be used for young children or
in patients where there is poor compliance, although its
rapid clearance from the oral cavity results in concentra-
tions falling to sub-therapeutic levels fairly quickly.
Similarly, the oral rinse is relatively ineffective, because of
the short contact time with the oral mucosa. Further, it
contains sucrose and increases the risk of dental caries
(Greenspan, 1994). In contrast, the pastilles and lozenges
can be sucked slowly and hence have a longer duration of
action. Further, the sweetened formulations of pastilles
and lozenges result in better patient compliance, and,
due to their prolonged retention, pastilles can be expect-
ed to be a better fungicidal agent than the suspension
(Millns and Martin, 1996). Nystatin pastilles are ideal for
the treatment of Candida-associated denture stomatitis
(Martin et al., 1986), and could be used to prevent out-
breaks or recurrence of oral candidosis in HIV-infected
patients (MacPhail et al., 1996). However, since these are
also sweetened with sucrose, it will increase the risk of
causing dental caries and may be contraindicated in den-
tate, caries-prone individuals.
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Some studies have shown that a slow-release system
with nystatin provides rapid clinical and mycological
improvement in patients with oral candidosis. This slow-
release form, kept in the mouth and not swallowed, is
sugar-free and offers a prolonged contact time. It has been
more effective than the pastilles for up to a week after
treatment. Nystatin has also been incorporated into a
controlled drug delivery system and marketed as a mucos-
al oral therapeutic system (MOTS). In a study of HIV-
infected patients with oral candidosis, the MOTS was
shown to be more effective than the oral nystatin pastilles
in lesion resolution (Samaranayake and Ferguson, 1994).
Although the MOTS appears to be a significant step for-
ward in the oral delivery of nystatin, further studies are
warranted prior to its general release.
Nystatin has been studied for its effectiveness for
eradicating yeasts from denture surfaces. In a study
where the effectiveness of a denture-soaking nystatin
solution was evaluated for the treatment of oral candi-
dosis in old, chronically ill, institutionalized adults, the
outcome was not satisfactory (Banting et al., 1995).
Although the clinical signs and symptoms of oral candi-
dosis were resolved in all these subjects following thera-
py, the presence of invasive candidal hyphae was detect-
ed in approximately 80% of tissue and/or dentures. Since
there are more appropriate disinfectant agents such as
hypochlorite and chlorhexidine gluconate for the
overnight disinfection of dentures, the use of nystatin for
this purpose is questionable and cannot be condoned.
The effects of low concentrations of nystatin on the
pathogenic attributes of Candida, such as their adhesion
to host surfaces and their proteolytic activity, are not
widely known. Nystatin, like amphotericin B, is capable
of suppressing adhesion of C. albicans to buccal epithe-
lial cells both in vivo and in vitro (Macura, 1988;
Vuddhakul et al., 1988; Abu-El Teen et al., 1989; Darwazeh
et al., 1997), and also to vaginal epithelial cells (Braga et
al., 1996). Further, nystatin was shown to be capable of
reducing oropharyngeal colonization by C. albicans in
CD4+ T-cell-deficient mice (Flattery et al., 1996), and
reducing candidal adhesion to denture acrylic pre-treat-
ed with the drug (McCourtie et al., 1986). In addition, the
ability of nystatin to cause inhibition of germ tube for-
mation by C. albicans has also been reported (Abu-El
Teen et al., 1989). Since nystatin acts on the candidal
cell wall, the foregoing effects, which adversely modu-
late the pathogenic attributes related to the outer sur-
face of the yeast, are not surprising.
The proteolytic activity of oral C. albicans isolates in
vitro is also curtailed by nystatin (Wu et al., 1996).
However, similar to amphotericin B, exposure of C. albi-
cans to sub-MIC of nystatin has resulted in an increased
resistance to apo-lactoferrin-mediated cell death
(Nikawa et al., 1994).
Several topical preparations of nystatin can be used
in the treatment of oral candidosis. These include: dis-
solved vaginal tablets (100,000 IU), 1 tablet 3 times a day;
dissolved pastille (100,000 IU), 1-2 pastilles 3-4 times a
day; ointment/cream to be applied to commissures 3
times a day; and oral suspension (100,000 units/mL) 4
times a day, continued for several days after post-clinical
healing (Table 3; Greenspan, 1994).
(c) Natamycin
Natamycin is active against Candida when applied topi-
cally but has a broader range of activity against fungi
than do the other two polyenes. For oral use, it is pre-
pared as a 1% suspension, but ointment and tablets are
also available (Samaranayake and Ferguson, 1994).
However, this drug is not widely used.
(B) AZOLE ANTIFUNGAL AGENTS
These agents are classified into two groups: (1) the imi-
dazoles-clotrimazole, econazole, fenticonazole, iso-
conazole, ketoconazole, miconazole, sulconazole, and
tioconazole; and (2) the triazoles-fluconazole and itra-
conazole.
The azoles are becoming increasingly popular in the
management of oral candidosis (Greenspan, 1994;
Samaranayake and Ferguson, 1994). Indeed, fluconazole
is the drug of choice in the treatment of oro-pharyngeal
candidosis in HIV infection. The azole antifungals act by
inhibition of cytochrome p-450 enzyme that is involved
in cell membrane synthesis in fungi. The principal target
is 14ot-demethylase, which converts 14ox-methylsterols
to ergosterol in the fungal cell membrane. Therefore,
they cause alteration of the fungal cell membrane by
blocking the 14a-demethylation step in the synthesis of
ergosterol (depletion of ergosterol and accumulation of
14(x methylsterols), an important constituent of fungal
cell membrane, which thus becomes permeable to intra-
cellular constituents and leads to alterations in several
membrane-associated functions. Imidazoles, in addition,
interfere with fungal oxidative enzymes to cause lethal
accumulation of hydrogen peroxide. The selective toxici-
ty of azoles is due to their differential affinities for mam-
malian and fungal cytochrome p-450 (Lambert and
O'Grady, 1992; Finch and Snyder, 1994; Lesse, 1995).
Clotrimazole, econazole, fenticonazole, isoconazole,
miconazole, sulconazole, and tioconazole are used for
local treatment. However, miconazole can also be given
by mouth for oral and intestinal infections.
Ketoconazole, fluconazole, and itraconazole are used for
both local and systemic candidoses.
(a) Clotrimazole
Clotrimazole has a broad spectrum of activity, being anti-
candidal as well as anti-staphylococcal, and is primarily
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fungistatic (Table 3; Samaranayake and Ferguson, 1994).
It is mainly used in the management of superficial can-
didal infections in the oral cavity, skin, and vagina.
Topical application results in adequate therapeutic con-
centrations in the epidermis or the mucosa. It is particu-
larly effective in managing oropharyngeal candidosis,
especially in immunocompromised, such as HIV-infect-
ed, patients (Greenspan, 1994), and recipients of renal
transplants (Gombert et al., 1987). It is widely used as a
first-line treatment of oral candidosis, especially in the
USA. As a cream, it is particularly useful in the treatment
of angular cheilitis, due to its dual action on both yeasts
and staphylococci (Greenspan, 1994).
Clotrimazole is known to suppress candidal adhe-
sion to human buccal epithelial cells, a factor which may
aid its therapeutic efficacy (Macura, 1988). Further, sub-
inhibitory concentrations of clotrimazole have been
shown to curtail the proteinase production by oral C. albi-
cans isolated from HIV-positive and HIV-negative individ-
uals (Wu et al., 1996). In contrast, clotrimazole had no
effect on the adherence of C. albicans to vaginal epithelial
cells, in vitro, regardless of whether the drug was used to
pre-treat the fungi or the vaginal epithelial cells or was
added to the yeast/vaginal cell mixture (Odds and
Webster, 1988).
When applied topically, clotrimazole is well-tolerat-
ed. Adverse reactions are minor and rare, and include
local skin irritation, vomiting, and nausea. Abdominal
cramps, increased urination, and elevated liver SGOT
levels have also been reported (Finch and Snyder, 1994).
Clotrimazole is available in the form of 1% cream
which can be applied to commissures three times a day,
and oral troche (10 mg) to be used dissolved 5 times a
day. Other forms-such as lozenges, vaginal creams, and
vaginal tablets-are also available for topical use (Lesse,
1995). The most common method of delivery of clotrima-
zole in oral candidosis is the use of a troche, available in
10-mg units. Slow dissolution in the mouth is thought to
result in binding of clotrimazole to the oral mucosa,
which is then gradually released to maintain a fungistat-
ic concentration for several hours. Patient compliance is
said to be enhanced by the more pleasant taste of clotri-
mazole as compared with the bitter flavor of certain nys-
tatin preparations, such as tablets and vaginal pessaries,
which are specifically not formulated for oral use
(Samaranayake and Ferguson, 1994).
(b) Miconazole
Miconazole, like clotrimazole, has a broad spectrum of
activity against fungi, including C. albicans. It is also effec-
tive against some Gram-positive bacteria, such as
staphylococci, and hence is useful in the management of
angular cheilitis where concurrent bacterial and fungal
infection may be present (Martin, 1990).
Miconazole can be given either topically, intra-
venously, or intrathecally. Only small amounts are
absorbed through the skin or from vaginal mucous mem-
brane. Serum concentrations as high as 7.5 mg/L, 15 min
after an infusion of a large dose of 100 mg, have been
reported (Lambert and O'Grady, 1992). Initial half-life of
the drug is about 20 to 30 min, but following continuous
drug administration, it is increased to about 24 hrs.
Miconazole is rapidly metabolized in the liver. Excretion
is essentially non-renal and is eliminated by hepatic
metabolism, mainly in the bile. There is good penetra-
tion of the drug into inflamed joints, eyes, and the peri-
toneal cavity. Penetration into saliva, sputum, and the
CNS is poor (Finch and Snyder, 1994).
Miconazole is effective in all types of oral candidosis,
including chronic mucocutaneous candidosis. It is also
used in vulvovaginitis caused by C. albicans. The systemic
use of miconazole has been largely superseded by the
availability of other, less toxic, drugs such as ketocona-
zole and fluconazole (Finch and Snyder, 1994).
Low concentrations of miconazole are capable of
suppressing candidal adhesion to buccal epithelial cells
(Brenciaglia et al., 1986; Vuddhakul et al., 1988; Abu-El
Teen et al., 1989) and inhibiting germ tube formation in C.
albicans (Borgers et al., 1979; Johnson et al., 1983; Abu-El
Teen et al., 1989). In contrast, such inhibitory effect on
germ tubes was not seen in another study (Brenciaglia et
al., 1986). Interestingly, as is the case with clotrimazole,
proteinase production by oral C. albicans was also cur-
tailed by sub-MIC of miconazole (Wu et al., 1996).
Side-effects after the topical use of miconazole are
few and uncommon. Burning and skin maceration can
occur following cutaneous use. Itching, burning,
urticaria, headache, and cramps have been associated
with the use of vaginal preparations. The most common
side-effect after intravenous use is thrombophlebitis.
Nausea may develop in some cases. Rarely, anaphylaxis
and cardiotoxicity can occur (Finch and Snyder, 1994).
Oral anticoagulants such as warfarin are widely pre-
scribed in the management of deep vein thrombosis,
pulmonary embolism, and patients with prosthetic heart
valves. Systemic antifungal drugs of the azole group are
known to enhance the anticoagulant effect of warfarin
(Baciewicz et al., 1994). Recently, it has been reported that
the concurrent use of miconazole oral gel for the treat-
ment of oral candidosis resulted in potentially life-
threatening derangement of warfarin anticoagulation
(Table 3; Ariyaratnam et al., 1997; Ezsias et al., 1997;
Pemberton et al., 1998).
Tablets, oral gel, intravenous injections, and topical
and vaginal preparations are available for the treatment
of candidosis. Miconazole cream is a very effective deliv-
ery mode for angular cheilitis lesions caused by Candida
and Staphylococcus aureus (Table 3). Another advantage is
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that the drug can be administered empirically when a
microbial report is not available or when the facility to
identify the exact nature of the infective agent is inac-
cessible (Samaranayake and Ferguson, 1994).
Miconazole has been formulated into a lacquer and is
effective in the treatment of Candida-associated denture
stomatitis. At least two studies have reported that a sin-
gle application of a miconazole lacquer painted over the
fitting surface of the denture, as a slow delivery agent,
considerably reduces the numbers of Candida on the den-
ture surfaces for a substantial period of time, and leads
to a clinical resolution of the mucosal lesion (Konsberg
and Axell, 1994; Dias et al., 1997).
(c) Ketoconazole
Ketoconazole is effective against a wide spectrum of
fungi and yeasts, including Candida spp., but, unlike
other azoles such as miconazole, it has no antibacterial
activity (Martin, 1990). It has been used in the manage-
ment of cutaneous, oral, esophageal, and vaginal
Candida infections for several years (Lesse, 1995).
Ketoconazole has no place in the treatment of primary
oral candidoses, and its main indication is for sec-
ondary oral candidoses such as in chronic mucocuta-
neous candidosis (Samaranayake and Ferguson, 1994).
However, triazoles such as fluconazole are being
increasingly used for the latter diseases.
Mucosal candidoses of the mouth and esophagus
respond well to ketoconazole, although there is little evi-
dence to suggest that the latter is better than nystatin in
granulocytopenic patients (Finch and Snyder, 1994). On
the contrary, ketoconazole has been shown to be superi-
or to nystatin in reducing oropharyngeal candidal colo-
nization in mice depleted of CD4+ lymphocytes (Flattery
et al., 1996). However, when 85 HIV-positive patients with
oral candidosis were evaluated for response to systemic
antifungal treatment with ketoconazole, 65 responded
with complete clinical remission to 200 mg daily, after
seven days of ketoconazole treatment, even though 81%
of post-treatment cultures remained positive (Silverman
etal., 1996).
Unlike other imidazoles, ketoconazole is readily
absorbed after oral administration, especially at an
acidic pH. However, absorption is variable, with peak
plasma levels of approximately 3.5 mg/mL achieved 1-2
hrs after administration of 200 mg. The passage of keto-
conazole into the cerebro-spinal fluid is generally poor
and unreliable, since greater than 90% is bound to serum
protein during bodily distribution. It is metabolized in
the liver, and inactive metabolites are excreted, largely in
bile and, to a smaller extent, in urine (Lambert and
O'Grady, 1992; Finch and Snyder, 1994).
Though the mechanisms by which ketoconazole
reduces mucosal colonization are not fully understood a
marked reduction of germination and adhesion of C. albi-
cans to vaginal and buccal epithelial cells following expo-
sure to ketoconazole has been reported (Johnson et al.,
1983; Sobel and Obedeanu, 1983; Macura, 1988;
Vuddhakul et al., 1988; Abu-El Teen et al., 1989). In con-
trast, one group has reported that the adhesion of C. albi-
cans to vaginal epithelial cells, in vitro, was not signifi-
cantly altered when the drug was used to pre-treat the
fungi or the vaginal cells or was added to the fungal/vagi-
nal cell mixture (Odds and Webster, 1988).
The most common adverse reactions to ketocona-
zole are gastro-intestinal intolerance, with nausea and
vomiting. Hepatotoxicity is not uncommon but is gener-
ally asymptomatic and accompanied by a reversible ele-
vation of serum transaminase (Table 3). Care has to be
taken during administration of ketoconazole, since fatal
hepatotoxicity and nephrotoxicity have been reported.
Liver function tests should be performed throughout any
prolonged ketoconazole therapy, and treatment should
be discontinued in patients with progressively increasing
transaminase levels (Odds, 1994). In subclinical adreno-
corticosteroid deficiency, ketoconazole blocks steroid
synthesis in host cells. Depression of testosterone
biosynthesis can manifest as painful gynacomastia, loss
of libido, and sometimes loss of hair (Lambert and
O'Grady,1992). It is also a potential teratogenic agent
(Fromtling, 1984). Because of the possible effects on the
liver and steroid metabolism, it should not be used as a
first-line treatment for mucosal or cutaneous infections.
But if used carefully, it can be very effective, and the risk
and side-effects relatively minor (Martin, 1990).
Many drug interactions are seen with ketoconazole.
Some are mild; others may have life-threatening conse-
quences. Ketoconazole is capable of decreasing the
hepatic metabolism of non-sedative antihistamines such
as terfenadine and astemizole, which can lead to
increased levels of the latter and its metabolites, with
resultant arrhythmias, tachycardia, and, rarely, death
(Lesse, 1995). Similarly, ketoconazole can suppress the
metabolism of cyclosporine, leading to elevated concen-
trations and accompanying profound immunosuppres-
sion and renal dysfunction, which may be life-threaten-
ing. Absorption of ketoconazole may be reduced by
antacids and H2-receptor blockers such as cimetidine
and ranitidine. Rifampin, a potent inducer of hepatic
metabolizing enzymes, can decrease ketoconazole con-
centration in serum (Lesse, 1995).
Tablets, suspensions, and creams of ketoconazole
are available. Depending on the infection, a 200- to 400-
mg tablet once daily is the dosage for systemic use
(Lambert and O'Grady, 1992; Greenspan, 1994). A 2%
cream can be successfully applied to commissures
three times a day in chronic hyperplastic candidosis.
As opposed to the imidazole antifungals discussed
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above, itraconazole and fluconazole are triazoles, which
differ somewhat in their pharmacological effects.
Itraconazole is water-insoluble and lipophilic, and
requires a lower pH to be ionized, as is true of ketocona-
zole; it is highly protein-bound and is excreted in bile.
Fluconazole, on the other hand, is water-soluble and
does not require a lower gastric pH for absorption; it is
poorly bound to plasma protein and is eliminated by
renal excretion. An important aspect of fluconazole is
that it reaches high concentrations in the normal and
inflamed CNS (Finch and Snyder, 1994). A major thera-
peutic advantage of triazoles is that they are more spe-
cific than the imidazoles for the fungal rather than the
mammalian cytochrome p-450 enzyme (Lesse, 1995),
with resultant lower toxicity and fewer side-effects.
(d) Fluconazole
Fluconazole has a broad spectrum of antifungal activity.
It is active against most strains of C. albicans but is less
active against non-albicans Candida species, particularly C.
krusei and C. glabrata, which are intrinsically resistant to
the drug (Van't Wout, 1996; Samaranayake, 1997; White et
al., 1998). In vitro sensitivity of this drug is highly depen-
dent on the test conditions. Thus, it is not unusual to
obtain very high MIC values, in vitro, for strains which are
responsive to the drug in vivo (Minguez et al., 1994).
Further, it has been shown that although fluconazole is
remarkably more effective than ketoconazole in the treat-
ment of candidal infections (Martin, 1989), its growth-
inhibitory activity against C. albicans, in vitro, is consider-
ably less than that of ketoconazole (Troke et al., 1988).
Interestingly, it has been shown that fluconazole 400 mg
daily is effective against oropharyngeal and esophageal
candidosis in a patient with endocrinopathy syndrome,
despite the infecting C. albicans strains being resistant to
azole antifungals in vitro (Field et al., 1996).
Fluconazole is given either orally or intravenously. It
is well-absorbed after oral administration, and peak
serum concentrations are reached within 2-4 hrs. What
distinguishes fluconazole from many other azoles is this
excellent absorption from the gastro-intestinal tract,
coupled with a very long serum half-life. The half-life in
adults ranges between 27 and 37 hrs. It also differs from
other azole antifungals in being weakly protein-bound in
serum. This helps in its excellent passage into most body
sites (Lambert and O'Grady, 1992). Unlike other azoles,
fluconazole is not metabolized in man, and approxi-
mately 80% is excreted, largely through the kidney,
unchanged (Finch and Snyder, 1994). It follows, there-
fore, that fluconazole has an almost negligible effect on
hepatic function as compared with other azoles, which
are metabolized mostly in the liver, leading to possible
hepatotoxicity.
Though fluconazole was introduced in late 1980's,
there is a considerable amount of data based on its effi-
cacy in the management of mucosal/oral candidoses.
Some of this information is given below. The high sys-
temic absorption of fluconazole has been useful in treat-
ing oral candidosis in HIV-infected patients, and it is now
considered the drug of choice for candidoses in HIV dis-
ease (Dupont and Drouhet, 1988; Lucatorto et al., 1991).
It has been shown that weekly fluconazole (200 mg) is
safe and effective in preventing oropharyngeal and vagi-
nal candidosis, and this regimen has a useful role in the
management of HIV-infected patients who are at risk for
recurrent mucosal candidosis (Schuman et al., 1997).
Further, when human immunodeficiency virus (HIV)-
infected patients with oropharyngeal candidosis were
randomly assigned to receive 14 days of therapy with a
liquid suspension of fluconazole (100 mg daily) or liquid
nystatin (50,000 IU, four times daily), it was found that
fluconazole oral suspension as a systemic therapy was
more effective than liquid nystatin as a topical therapy in
the treatment of oral candidosis, and provided a longer
disease-free interval before relapse (Pons et al., 1997).
When the effectiveness of antifungal treatment for thrush
in HIV-infected patients was observed, it was shown that
both fluconazole and clotrimazole were equally effective
in treating thrush, but mycological cure occurred more
often with fluconazole (Sangeorzan et al., 1994). Further,
administration of fluconazole in capsule form has proved
effective in the prophylaxis and treatment of mucosal
candidosis in immunocompromised patients, and, in
addition, a topical effect could be obtained in oro-pha-
ryngeal candidosis with a fluconazole suspension
(Wildfeuer et al., 1996), possibly due its oral delivery via
gingival crevicular fluid and saliva. For instance, it has
been shown that, after a single dose, fluconazole (100
mg) achieved higher salivary concentrations than did
ketoconazole (400 mg). This may explain the increased
clinical efficacy of fluconazole in the treatment of oro-
pharyngeal candidosis (Force and Nahata, 1995).
Fluconazole has also been shown to be effective in
resolving palatal candidosis at a dose nine times lower
than that of ketoconazole (Martin, 1989). It has been
successfully used in the management of candidal leuko-
plakia (Lamey et al., 1989), cheilo candidosis la rare can-
didal infection of the lips due to associated intra-oral
candidal carriage, actinic lip damage, and Sjogren's syn-
drome (Napier et al., 1996)1, and oral candidosis in bone
marrow transplant patients (Goodman et al., 1992), in
malignant disease (Ninane et al., 1994; Lesse, 1995), and
in acute leukemia (Winston et al., 1993). In recent stud-
ies, fluconazole (100 mg/daily) was compared with
clotrimazole (10 mg 5 times a day) in patients with oral
candidosis. At the end of two weeks, fluconazole was
more effective in clearing Candida, and those treated
with fluconazole remained free of infection for a longer
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period than those treated with clotrimazole (Hay, 1990;
Koletar et al., 1990; Pons et al., 1993). In patients with
Candida-associated denture stomatitis, fluconazole is
effective (Budtz-J0rgensen, 1990; Bissell et al., 1993),
especially when administered along with an oral anti-
septic such as chlorhexidine (Hay, 1990; Kulak et al.,
1994; Arikan et al., 1995).
Adhesion of Candida to epithelial cells, a major deter-
minant of candidal colonization, is significantly inhibited
by fluconazole (Darwazeh et al., 1991). Since fluconazole
is secreted in high concentrations in saliva (Laufen et al.,
1995; Wildfeuer et al., 1996), it may interfere with the syn-
thesis or structure of Candida receptors on buccal epithe-
lial cells, which may help reduce candidal colonization.
Further experimental evidence suggests that sub-
inhibitory concentrations of fluconazole are capable of
reducing the adhesiveness of Candida to vaginal mucosal
cells, though to a lesser extent than nystatin (Braga et al.,
1996). On the contrary, fluconazole showed superior effi-
cacy in reducing oral colonization by C. albicans in mice
depleted of CD4+ T-lymphocytes (Flattery et al., 1996).
Further, systemic fluconazole therapy significantly inhib-
ited the adherence of C. albicans to buccal epithelial cells
of oral candidosis patients, and also interfered with the
synthesis of candidal receptor-like proteins on the sur-
faces of buccal epithelial cells (Shaoxi et al., 1996).
Fluconazole is well-tolerated, and side-effects such
as nausea, headache, and gastro-intestinal and abdom-
inal discomfort are usually mild and subjective (Table
3). It may cause elevation of liver enzymes and an aller-
gic rash. jaundice and abnormal liver function tests
were seen in some patients treated with fluconazole in
HIV-related oral candidal infection (Franklin et al.,
1990). It is also reported that a patient with AIDS-relat-
ed oropharyngeal candidosis treated with fluconazole
developed a dose-related liver dysfunction (Wells and
Lever, 1992). Since animal studies have demonstrated
embryotoxicity, it is prudent for fluconazole to be
avoided in pregnancy (Aleck and Bartley, 1997;
Laurence et al., 1997).
Although fluconazole has less activity on mam-
malian cytochrome P-450 enzymes than does ketocona-
zole, and although the drug interactions are fewer, flu-
conazole nevertheless has significant interactions with
several medications. Despite the paucity of reports of
interactions with terfenadine and astemizole (non-seda-
tive antihistamines), the structural analogy of flucona-
zole and ketoconazole indicates that non-sedating anti-
histamines should not be administered with fluconazole.
By decreasing the hepatic metabolism of several agents,
fluconazole can bring about high serum concentrations
of such agents when administered concurrently. For
instance, decreased clearance of cyclosporine may result
in significant immunosuppression, leukopenia, and renal
dysfunction, and a similar interaction with phenytoin,
warfarin, and hypoglycemics can produce toxic pheny-
toin concentrations in serum, prolonged prothrombin
times, and hypoglycemia, respectively (Baciewicz et al.,
1994; Lesse, 1995).
Fluconazole is available in capsule and intravenous
formulations. For adults, the oral and intravenous
dosage is 50 mg daily for 7-14 days for the treatment of
oropharyngeal candidosis, while 50 mg daily for 14-30
days is recommended for the treatment of esophageal
candidosis (Table 3; Lambert and O'Grady, 1992).
(e) Itraconazole
Itraconazole is a lipophilic drug that is well-absorbed
after oral administration and has a wide spectrum of
antifungal activity. It is effective in various superficial
mycoses, including oral candidosis due to C. albicans as
well as C. krusei and C. glabrata (Van Cutsem, 1994).
Following drug administration, peak serum concentra-
tions are reached 2-4 hrs later, and greater than 99% is
bound to plasma proteins. It requires a low gastric pH for
absorption. In lipophilic tissues, the concentration of the
drug is 2 to 20 times higher than the plasma concentra-
tion. It is metabolized in the liver; excretion is biliary
(Lambert and O'Grady, 1992; Finch and Snyder, 1994).
Since C. krusei and C. glabrata are intrinsically resis-
tant to fluconazole (Samaranayake, 1997), itraconazole is
an ideal alternative in the management of patients
infected with fluconazole-resistant Candida (Ruhnke et al.,
1994; Phillips et al., 1996; Laguna et al., 1997). For
instance, when 40 AIDS patients suffering from flucona-
zole-resistant oro-pharyngeal candidosis were treated
with oral itraconazole solution (200-800 mg per day), the
condition was significantly improved (Eichel et al., 1996).
In the treatment of oral candidosis, one study has shown
that patients treated with itraconazole (200 mg/day) had
a longer period of remission than did patients treated
with ketoconazole (Smith et al., 1988). In two separate
comparative studies, itraconazole produced a faster
response rate and a longer time before relapse than did
clotrimazole (Blatchford, 1990).
Generally, itraconazole is well-tolerated, though
gastro-intestinal disturbances, headache, and dizziness
have been reported (Finch and Snyder, 1994). Transient,
asymptomatic transaminase elevations and
hypokalemia have also been reported (Lambert and
O'Grady, 1992). As with other azoles, cyclosporine clear-
ance is reduced by itraconazole, and serum concentra-
tions of the former should be monitored to prevent the
occurrence of potentially major complications. Similarly,
simultaneous use of itraconazole and either terfenadine
or astemizole should be avoided. Itraconazole has been
reported to decrease digoxin clearance, and serum
digoxin concentrations should be measured during con-
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current therapy (Lesse, 1995).
Itraconazole is available in capsule and oral solu-
tion forms. The adult oral dose is 100 mg daily for 15
days for oro-pharyngeal candidosis (Table 3; Lambert
and O'Grady, 1992). The availability of an oral solution
may be advantageous over the capsule formulation,
due to the fact that it would be easier to swallow for
patients with severe oro-pharyngeal candidosis
(Blatchford, 1990).
(f) Drawbacks of azoles
All azoles are fungistatic, not fungicidal. This is an impor-
tant consideration in the treatment of chronic, immuno-
compromised patients, such as those with AIDS, and in
the treatment of infections at critical sites (e.g., candidal
meningitis) (Siegman-Igra and Raban, 1992). Further,
none of the azoles is entirely benign, and they are expen-
sive. Hepatotoxicity may be common to all of them
(Lesse, 1995), and the potential for endocrine toxicity
exists, particularly at higher doses.
Although antifungal drug resistance has been exten-
sively reviewed recently (White et al., 1998), some points
are worthy of note. The emergence of resistance to the
triazoles, particularly to fluconazole, is disturbing.
Fluconazole resistance has been defined as the persis-
tence of clinical candidosis despite treatment with 100
mg daily for at least 7 days (Dupont et al., 1996). It is now
a real clinical problem in patients with HIV disease
(Barchiesi et al., 1995; Johnson et al., 1995; Heald et al.,
1996; McGinnis and Rinaldi, 1996; Dromer et al., 1997;
Klepser et al., 1997; White et al., 1997). A recent study
found that at least one fungus resistant to fluconazole
was isolated from 41% of patients with AIDS (Maenza et
al., 1997). Fluconazole-resistant Candida is also a prob-
lem, especially in intravenous drug users (Chavanet et at.,
1994) and in those with systemic candidiasis (Siegman-
Igra and Raban, 1992). It has also been reported in
patients with chronic mucocutaneous candidosis (Field
etal., 1996).
There is also evidence of cross-resistance between
fluconazole-resistant C. albicans and non-albicans isolates
to ketoconazole, miconazole, and itraconazole (Le
Guennec et al., 1995; Maenza et al., 1996). Nonetheless,
other studies have indicated that ketoconazole and itra-
conazole may be clinically effective, despite some cross-
resistance (Laguna et al., 1997). Itraconazole, in particu-
lar, may remain effective (Martinez et al., 1997), though
about 30% of fluconazole-resistant isolates may still be
resistant to itraconazole (Cartledge et al., 1997).
Fortunately, there may still be a clinical response to
amphotericin B in fluconazole-resistant candidiasis
(Maenza et al., 1996; Revankar et al., 1996).
Three main resistance patterns of fluconazole have
been identified: first, a progressive increase in the MIC
over weeks or months, and infection with the same
Candida strain; second, a sudden or rapid failure of ther-
apy, with the emergence of a new resistant strain; and
finally the acquisition of a new and resistant organism
from a sexual partner.
Fluconazole resistance appears to result from muta-
tion (Barchiesi et al., 1996) and may appear in patients
who have received no fluconazole, since resistance may
be transferred (Goff et al., 1995; Revankar et al., 1996).
Thus, transfer of fluconazole-resistant Candida species
between patients has been documented (Barchiesi et al.,
1995; Boerlin et al., 1995), perhaps due to the patients'
sexual activity (Dromer et al., 1997). Further, previous flu-
conazole use and severe immune defects are risk factors
for fluconazole resistance (Revankar et al., 1996; Laguna et
al., 1997; Tumbarello et al., 1997). There is also evidence
that intermittent fluconazole or low-dose therapy is
more likely to result in the emergence of resistance iso-
lates than continuous and/or high-dose therapy
(Chavanet et al., 1994; Ruhnke et al., 1994; Heald et al.,
1996). Azole resistance can also arise because of changes
in the candidal target enzyme 14ot sterol demethylase,
reduced fungal membrane permeability to azoles, or
increased efflux of azoles from the organisms (Sanglard
et al., 1995; Clark et al., 1996; Lamb et al., 1997; Marichal et
al., 1997).
Potential resistance to fluconazole may be predicted
by rather tedious, in vitro, assays proposed by the US
National Committee for Clinical Laboratory Standards
(NCCLS). However, the commercially available "E test"
could be used for this purpose, since it is simple and
reliable (Dannaoui et al., 1997). Others have proposed
newer methods of susceptibility testing using flow
cytometry (Ramani et al., 1997).
(g) Treatment of fluconazole-resistant candidosis
Management strategies for fluconazole-resistant cases
include: (a) higher oral doses of fluconazole, up to 600
mg per day; (b) use of a fluconazole suspension as an oral
rinse (Martins and Rex, 1997); and (c) the use of systemic
ketoconazole 400 mg per day or itraconazole 200-400 mg
per day (Ng and Denning, 1993). Several reports indicate
that itraconazole is an effective alternative for flucona-
zole-resistant candidosis (Dupont et al., 1996; Phillips et
al., 1996; Cartledge et al., 1997). Amphotericin B used
orally, intravenously, or liposomally may also be effective
(Dewsnup and Stevens, 1994; Nguyen et al., 1996).
(C) DNA ANALOGUES
The drug 5-fluorocytosine is rarely, if ever, used in the
management of oral candidoses. However, a brief
overview is provided for the sake of clarity and compre-
hensiveness. The DNA analogue 5-fluorocytosine is a
fungistatic agent which is highly effective against all
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Candida spp. After administration, it is transported into
the fungal cell by the action of cytosine permease, and
inside the cell, is converted to form the active metabolite
5-fluorouracil by cytosine deaminase. 5-fluorouracil is
then incorporated into RNA in place of uracil, with
resulting abnormalities of protein synthesis. In addition,
it blocks thymidylate synthetase, causing inhibition of
DNA synthesis. Since the mammalian cells lack cytosine
deaminase, they are not affected by the drug (Lambert
and O'Grady, 1992; Finch and Snyder, 1994).
This drug is well-absorbed from the intestinal tract
after oral administration, and the serum half-life of 5-
fluorocytosine is between 3 and 6 hrs. Serum protein
binding is minimal and is widely distributed, with CSF
concentrations in the region of 75% of serum concentra-
tions. 5-Fluorocytosine is mainly excreted through the
renal route, thus necessitating modifications of the
dosage regimen in renal dysfunction (Lambert and
O'Grady, 1992).
Its principal use is in combination with amphotericin
B in the treatment of deep forms of systemic candidosis,
including fungal endocarditis. As C. albicans rapidly
becomes resistant to 5-fluorocytosine, combination
therapy with another antifungal, usually amphotericin B,
is recommended. However, such combination increases
the risk of adverse effects (Laurence et al., 1997).
The most important toxic effect of 5-fluorocytosine
is marrow aplasia, which can occur with long-term ther-
apy and high serum concentrations. Vomiting, diarrhea
and, rarely, more severe enteritis and hepatotoxicity can
also occur.
Tablets and intravenous infusions are available for
treatment, and the adult oral and intravenous dosage is
200 mg per kg body weight in four divided doses per day
(Lambert and O'Grady, 1992).
(D) OTHER ANTIFUNGAL AGENTS USED
IN ORAL CANDIDOSIS
(a) New antifungal agents
A vast array of new antifungal agents-such as
amorolfine, natifine, terbinafine, tolaftate (McGinnis
and Rinaldi, 1996), rilopirox (Braga et al., 1996), cilofun-
gin, pradimycin (Samaranayake and Ferguson, 1994),
voriconazole (Ruhnke et al., 1997), and benanomicin A
(Ohtsuka et al., 1997)-is either being marketed or
undergoing extensive clinical trials. However, there are
limited data on the oral pharmacodynamics of these
agents, despite the fact that most are clinically very
effective.
(b) Chlorhexidine
Since its introduction in the 1970s, chlorhexidine has
been used as an adjunct in the management of oral
candidoses (Budtz-J0rgensen, 1990). For instance, 0.2%
chlorhexidine gluconate has been successfully used as
a mouthrinse in the treatment of Candida-associated
denture stomatitis and in pseudomembranous candi-
dosis, while 2% suspension is used as an overnight den-
ture disinfectant.
Chlorhexidine gluconate has a bimodal action on
Candida. First, it is fungicidal, even at very low concentra-
tions, with MIC reaching 0.001% (Ellepola and
Samaranayake, 1999a). Second, it is capable of signifi-
cantly suppressing candidal adhesion to both inorganic
and organic substrates. Many studies have clearly
demonstrated the latter property of chlorhexidine glu-
conate, particularly in suppressing candidal adhesion to
denture acrylic surfaces (McCourtie et al., 1985, 1986;
Kamalakshi et al., 1992). Further, exposure of buccal
epithelial cells to chlorhexidine gluconate, either in vivo
or in vitro, significantly reduces the adhesion of Candida to
buccal cells (Tobgi et al., 1987; Audus et al., 1992).
Interestingly, this phenomenon persists regardless of
whether the buccal cells are derived from healthy sub-
jects or from patients with diabetes mellitus (Darwazeh et
al., 1994). Due to its multifaceted anti-candidal action,
mouthrinses containing chlorhexidine have been pro-
posed as an appropriate alternative to conventional anti-
fungals in the management of oral candidosis (Giuliana
et al., 1997). It is salutary to note that chlorhexidine and
nystatin should not be used simultaneously, since they
interact, forming chlorhexidine-nystatin complexes, ren-
dering both agents ineffective against Candida (Barkvoll
and Attramadal, 1989).
(c) Antifungal agents Incorporated
Into dental materials
Due to the recalcitrant nature of Candida-associated den-
ture stomatitis, several workers have attempted, with
some degree of success, to incorporate antifungals such
as nystatin into dental materials. For instance, nystatin
has been incorporated into denture liners as an alterna-
tive for the treatment of denture stomatitis (Douglas and
Walker, 1973). Further, miconazole and ketoconazole
have been shown to be effective in suppressing candidal
growth when combined with tissue conditioners (Quinn,
1985). In contrast, amphotericin B was completely inef-
fective when mixed with the tissue conditioner Visco-gel
(Thomas and Nutt, 1978).
When the feasibility of a sustained-release delivery
system for the treatment of denture stomatitis was
studied, in vitro, by means of four antifungals (chlorhex-
idine gluconate, clotrimazole, fluconazole, and nys-
tatin) incorporated into a tissue conditioner, it was
found that all drugs were released from the tissue con-
ditioner matrix with simultaneous inhibition of candi-
dal growth (Schneid, 1992). Although these reports
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indicate the in vitro inhibitory effects of antifungals on
candidal growth, the nutrient-rich environment and the
cleansing effect of the oral cavity are likely to minimize
the beneficial action in vivo (Graham et al., 1991; Okita et
al., 1991). Further, the dosages of the antifungals used
in these in vitro studies appear to be high, costly, and
impractical in clinical situations. In addition, the possi-
ble emergence of resistance organisms due to the con-
stant presence of the drugs in the oral environment can-
not be ruled out. Despite these caveats, slow-release
agents and the related improvements in technology
may be harnessed in future for the incorporation of
antifungals into dental materials.
(IV) Prophylaxis of Oral Candidosis
Those at greatest risk of fungal infection are compro-
mised patients with HIV disease or receiving anti-neo-
plastic chemotherapy, radiotherapy, immunosuppres-
sive therapy, or prolonged antibiotic therapy (Scully et
al., 1994; Lortholary and Dupont, 1997). Mucosal candi-
dosis contributes markedly to the morbidity of HIV-
infected patients, and, as stated earlier, it is the most
common fungal infection in such populations (Wheat,
1993). Further, Candida is by far the most common fun-
gal pathogen isolated from neutropenic patients and
represents 90% of all fungal infections in this group
(Varthalitis and Meunier, 1995). Candida is thus the most
common target for antifungal prophylaxis in all types of
immunodeficiencies. Hence, prophylactic anti-candidal
regimens need to be frequently prescribed (Lortholary
and Dupont, 1997). Such regimens could take the form
of intermittent or continuous therapy. The mode of such
therapy depends on several factors, including the sever-
ity of the underlying illness, frequency of recurrence of
the fungal infection, concurrent antibiotic therapy
(which promotes candidal growth), and the length of
therapy, as well as the Candida species isolated from the
patient.
The increasing resistance of C. albicans from HIV-
infected patients undergoing long-term fluconazole ther-
apy has become a major problem (Barchiesi et al., 1994;
Ruhnke et al., 1994; Rex et al., 1995a). Further, the recent
discovery of C. albicans resistance to other antifungal
drugs, such as amphotericin B and the other azoles, is
worrisome (Kelly et al., 1996; Le et al., 1996; White et al.,
1998). Emergence of antifungal resistance in other non-
albicans Candida species such as C. krusei, a phenomenon
which is increasingly common, has also been reported
(Pfaller, 1996; Samaranayake, 1996, 1997).
Often in the treatment of fungal infections, atten-
tion to the underlying cause will eliminate the need for
prolonged or repeated courses of treatment (Scully et al.,
1994). The most important prophylaxis regimen against
candidosis, therefore, is to minimize or eliminate fac-
tors which predispose to Candida infections (Lortholary
and Dupont, 1997). However, intermittent or continuous
antifungal treatment may be necessary when the under-
lying cause is incurable, as in HIV disease.
Prophylactic antifungal regimens should target not
only the host mucosal surfaces but also the inanimate
surfaces, such as prostheses, which may harbor yeasts
and initiate re-infection. A classic example of this is
denture plaque, which often contains Candida species.
Therefore, to prevent Candida-associated denture stoma-
titis, in both healthy and compromised patients, den-
ture cleansing that includes removal of Candida is a
necessary prerequisite. Denture cleansers can be cate-
gorized according to their main components: alkaline
peroxides, alkaline hypochlorites, acids, disinfectants,
and enzymes (Budtz-J0rgensen, 1990). Of these, the
proteolytic enzymes are found to be the most effective
against Candida. Others have claimed that a denture-
soaking solution containing benzoic acid completely
eradicates C. albicans from the surfaces (lacopino and
Wathen, 1992), as do 0.2% chlorhexidine gluconate
(Kamalakshi et al., 1992) and a protease-containing
denture soak (Odman, 1992). Though not very popular,
these agents can be used as an adjunct to mechanical
cleansing in preventing the recurrence of Candida-asso-
ciated denture stomatitis.
(V) Susceptibility Testing
In vitro susceptibility testing of antifungal agents is
becoming increasingly important because of the intro-
duction of new agents and the recovery of clinical iso-
lates that exhibit intrinsic (primary) resistance or devel-
op secondary resistance to the drug during therapy
(White et al., 1998). The primary objective of virtually all
in vitro susceptibility tests is to facilitate the prediction
of the efficacy of the antimicrobial agent on the out-
come of infection caused by a specific pathogen. It
should be borne in mind that, regardless of the purpose
of such testing, results obtained in a simple, well-
defined, and highly artificial in vitro system have intrin-
sic limitations in predicting the outcome of the clinical
infections. Thus, only a modest correlation exists
between in vitro results and clinical outcome, despite
decades of experience with standardized testing meth-
ods (Pfaller et al., 1997).
Susceptibility testing of fungi, including yeasts, pre-
sents numerous problems that are not encountered in
the evaluation of bacterial susceptibility to antibiotics.
Morphological variations, such as the yeast form and
hyphal form, differences in growth rates, and optimal
growth conditions have a profound effect upon the test-
ing methods (McGinnis and Rinaldi, 1996). Susceptibility
testing may be conducted in test tubes, petri dishes, or
microtiter trays. Flow cytometry (Pore, 1994; Ramani et
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TABLE 4
Reported in vitro Minimum Inhibitory Concentration Values (pg/mL) of Common Candida Species
against Widely Used Antimycotic Agents (McGinnis and Rinaldi, 1996)
Condida AMP* NYS MCZ CLT KETO ITR FLU 5-FC
Species
C. albicans 0.05-4 0.78-> 100 0.016-100 0.01-50 0.01-> 100 0.063-128 0.125-> 80 0.01-> 100
C. glabrata 0.05-> 100 1-> 50 0.016-64 0.25-25 1 2-128 - 0.01-> 100
C. guilliermondii 0.02-2 2-> 50 0.25 0.016-50 0.4-50 - - < 0.02-10
C. krusei 0.05-> 6.25 0.5-25 < 0.06-6.25 < 0.5-1 0.1-10 0.125-0.5 32-64 0.1-> 25
C. parapsilosis 0.02-> 6.25 1-> 50 0.016-32 0.016-12.5 < 0.12-> 64 0.06-> 128 0.5-4 < 0.025-> 100
C. tropicalis 0.04-16 0.5-50 0.016-33 0.016-4 <0.12-> 64 0.13-> 128 0.5-> 64 0.01-> 100
* Abbreviations: AMP, amphotericin B; NYS, nystatin; MCZ, miconazole; CLT, clotrimazole; KETO, ketoconazole; ITR, itraconazole; FLU, fluconazole;
and 5-FC, 5 fluorocytosine).
al., 1997) and "E tests" (Dannaoui et al., 1997) have been
recently added to this repertoire. In addition, numerous
other attributes-including the composition of the test
medium, the form and concentration of the inoculum,
the incubation temperature and duration, and the crite-
ria used as end points-have a pronounced impact upon
the MIC (Minimum inhibitory concentration) and MFC
(Minimum fungicidal concentration) values obtained
(McGinnis and Rinaldi, 1996). A simple technique to
ensure intra-laboratory reproducibility is to incorporate
a quality control (QC) isolate having known repro-
ducible MIC and MFC values with each in vitro suscepti-
bility test. Even with such strict control measures, the
results often lack specificity and suffer from significant
intra-laboratory variability.
Due to the difficulty in the interpretation of in vitro
susceptibility data, the National Committee for Clinical
Laboratory Standards in the USA (NCCLS, 1995) has
recommended several standard antifungal susceptibili-
ty testing methods for yeasts. Correlation of the in vivo
and in vitro activities of antifungal agents can be made,
to some degree, by such standardization, and hence all
workers in the field should refer to and adopt these
techniques to yield universally comparable data
(Anaissie et al., 1994; Rex et al., 1995b). Clinical applica-
tion and interpretation of antifungal susceptibility
tests have been reviewed recently (Pfaller et al., 1997;
Rex et al., 1997) and will not be further discussed here.
The MIC values of common Candida species against
widely used antifungals are given in Table 4 (McGinnis
and Rinaldi, 1996).
(VI) Post-antifungal Effect (PAFE)
Suppression of yeast growth that persists following lim-
ited exposure to antifungal agents has been termed the
"post-antifungal effect" (PAFE). This is an offshoot of a
new concept, termed the "post-antibiotic effect" (PAE),
that was introduced in relation to antibiotic use in the
management of bacterial infections (Craig and
Gudmundsson, 1996). It must be emphasized that the
PAFE arises due to prior exposure of yeasts to antifun-
gals for a short duration, rather than to continuous
exposure for a longer period of time, as in the case of
MIC determination.
Suppression of microbial growth is an inevitable
accompaniment during the PAFE period. However, what
is more interesting and intriguing is the associated
weakening of microbial virulence which may directly or
indirectly influence the host-parasite relationship (Shibl
et al., 1995). In clinical terms, the main significance of
the PAFE is the impact that it may have on the charac-
terization of the dosage regimens (Craig and
Gudmundsson, 1996). For instance, antifungal agents
with longer PAFE could be administered (against the
infective organism) with longer dosing intervals and vice
versa, without loss of efficacy and with lower frequency of
adverse effects (Turnidge et al., 1994).
Clinically, the goal with respect to treatment with
antifungal agents is to maintain the drug concentration
above the MIC for almost the entire dosing period
(Scalarone et al., 1991). Therefore, in the treatment of
candidal infections, it would be desirable if the clinicians
could rely on in vitro susceptibility tests to obtain critical
information regarding antifungal dosage regimens. But,
as discussed above, there is a lack of universally accept-
ed standardized procedures which provide treatment
guidelines that correlate well with the in vivo situation
with regard to the most effective dosage regimen (Pfaller
et al., 1997). Furthermore, when determining MIC, one
should remember that the fungi are continuously
exposed to a constant level of the antifungal agent,
whereas, in vivo, the organisms are exposed to fluctuating
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Figure 2. Growth curves of a C. albicans oral isolate following limited exposure to and subsequent removal of 5 antifungal drugs in vitro.
Note the suppression of growth due to exposure to the polyenes and the DNA analogue. The x-axis denotes the time, and the y-axis
denotes the optical density. The duration of PAFE was calculated according to the formula PAFE = T - C, where T was the time required for
the relative optical density of the drug-exposed cell suspension to reach the 0.05 absorbance level after removal of the drug, and C was
the time required for the relative optical density of the dru -free control cell suspension to reach the same absorbance level. Thus, T - C
expressed the time in which the antifungal agent was capable of causing growth suppression of the organism following limited exosure
to the drug (A, Control; B, Nystatin; C, Amphotericin B; D, 5-Fluorocytosine; E, Ketoconazole; and E, Fluconazole) (Ellepofa and
Samaranayake, 1 998a).
levels of the drug (Scalarone et al., 1992). This problem is
further exacerbated in the oral environment due to the
diluent effect of saliva and the cleansing effect of the oral
musculature. Thus, the PAFE may be considered a rele-
vant benchmark for determination of the dosage regimen
of an antifungal which could be used in tandem with MIC
values of the drug. The latter is the sole criterion cur-
rently used for this purpose.
The duration of the PAFE and even the presence or
absence of the PAFE are influenced by several factors
which essentially fall into three groups: the organism in
question, the drug being tested, and environmental fac-
tors, which are summarized in Table 5 (Scalarone et al.,
1991; Turnidge et al., 1994; Shibl et al., 1995; Craig and
Gudmundsson, 1996).
There is little information on the PAFE in Candida
species. Perusal of previous research indicates that sig-
nificant PAFE were produced by limited exposure of
Candida species to amphotericin B and 5-fluorocytosine
(Turnidge et al., 1994). While PAFE of several hours'
duration after exposure of C. albicans to 5-fluorocyto-
sine has also been observed (Scalarone et al., 1992), lit-
tle if any PAFE has been observed with the imidazoles
(Turnidge et al., 1994) and the triazole fluconazole
(Minguez et al., 1994). Similar observations have been
demonstrated on the PAFE of the polyenes, 5-fluorocy-
tosine, and the azoles in 10 isolates of oral C. albicans
(Ellepola and Samaranayake, 1998a; Fig. 2). More
recently, PAFE of several hours following brief expo-
sure to nystatin on non-albicans Candida species of oral
origin has been reported (Ellepola and Samaranayake,
1999b).
The mechanisms by which antimicrobials produce
the PAE in bacteria or the PAFE in fungi have not been
clearly explained (Zhanel et al., 1991; Shibl et al., 1995).
However, the three most commonly proposed mecha-
nisms are: (a) the limited persistence of the drug at the
microbial binding site, (b) the recovery from drug-
induced non-lethal damage to cell structures, and (c) the
time required for synthesis of new proteins and enzymes
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TABLE 5
Factors that Affect the Post-antifungal Effect (PAFE) of an Antimycotic Agent
Organismal Factors Drug Factors Environmental Factors
* Phenotypic and genolypic characteristics of * Mode of action of the drug * Type of growth medium
the organism * Exposure time to the drug * pH of the growth medium
* Inoculum size * Concentration of the drug * Incubating temperature
* Growth phase of the organism at the time * Combined use of antimicrobials * Mechanical shaking of the culture
of exposure
before resumption of cell growth (Craig and
Gudmundsson, 1996).
It is instructive to examine, in some detail, the possi-
ble mechanisms by which antimycotic agents elicit a
PAFE in Candida species. The polyenes alter the perme-
ability of the yeast cytoplasmic membrane by binding to
ergosterol, and a relatively prolonged period of time
would be required for the cells to recover before active
budding and multiplication could commence, thus elicit-
ing a lengthy PAFE (Ellepola and Samaranayake, 1998a,
1999). On the other hand, the DNA analogue, 5-fluorocy-
tosine, once within the yeast cell, is incorporated into
RNA in place of uracil, with resulting abnormalities of
protein synthesis and inhibition of DNA synthesis. The
long PAFE usually observed with 5-fluorocytosine may
represent the period in which there is abnormal protein
synthesis, and suppression of DNA synthesis prior to
commencement of normal cell division (Turnidge et al.,
1994; Ellepola and Samaranayake, 1998a). The azoles, on
the other hand, cause alterations in fungal cell mem-
branes by blocking the 14ac-demethylation step in the
biosynthesis of ergosterol. Interestingly, in contrast to the
polyenes and the DNA analogue, the inability to elicit a
significant PAFE by the azoles (Ellepola and
Samaranayake, 1998a) may reflect the fact that the drug-
induced effects are transient and readily reversible, or
that the limited period of exposure is inadequate for
these drugs to produce the desired effect.
It has been shown that, in bacteria, the PAE is not
merely restricted to suppression of microbial growth. The
other accompanying effects include changes in cell mor-
phology (Hanberger et al., 1993), inhibition of enzyme
and toxin production (Shibl et al., 1994), loss of adhesive
properties and reduction of cell-surface hydrophobicity
(Shibl et al., 1994; Ramadan et al., 1995), and increased
susceptibility to host humoral and cellular immunity
(Minguez et al., 1994; Ramadan et al., 1995). Many of these
effects are probably overlapping and closely linked.
Despite these observations in bacteria, the impact of
the PAFE on cellular attributes of Candida have not been
extensively investigated thus far. However, a few studies
documenting the effects of antimycotics on various
pathogenic attributes of oral C. albicans isolates during the
PAFE period are available. In one study, it has been
demonstrated that the polyenes (nystatin and ampho-
tericin B) and ketoconazole were capable of perturbing
germ tube formation in C. albicans following brief drug
exposure, while 5-fluorocytosine and fluconazole failed to
exert such an effect during the PAFE period (Ellepola and
Samaranayake, 1998b). In a separate study, it was found
that all these drugs were significantly able to inhibit
adhesion of Candida to denture acrylic surfaces during the
PAFE period (Ellepola and Samaranayake, 1998e). With
the exception of 5-fluorocytosine, similar suppression of
candidal adhesion to buccal epithelial cells was elicited
by the other antifungal agents during this period
(Ellepola and Samaranayake, 1998d). Cell-surface
hydrophobicity is a complementary factor involved in
yeast adhesion to host surfaces and is considered an
important pathogenic attribute of Candida. Our recent
studies have disclosed that the polyenes and ketocona-
zole are capable of effectively minimizing the relative
cell-surface hydrophobicity of oral C. albicans isolates
during the PAFE period, while such an effect was not
seen following limited exposure to 5-fluorocytosine and
fluconazole (Ellepola and Samaranayake, 1998c). Further
investigations, especially in relation to molecular
aspects, are warranted to elucidate these phenomena of
Candida during the PAFE period, and to translate these
effects for therapeutic purposes.
(VII) Conclusion
One major challenge in the management of patients with
oral candidosis, especially those who are compromised, is
to make a sensible selection from among the many anti-
fungal agents now available on the market. The mode of
action of the drug should be considered when an antimy-
cotic is selected. This is an important factor in the treat-
ment of patients chronically immunocompromised, such
as those with AIDS, where azoles, especially fluconazole,
should be the drug of choice. The polyenes should be rou-
tinely used in empirical therapy of primary oral candido-
ses, since the inappropriate use of the more useful azoles
as the first drug of choice may result in eventual emer-
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gence of resistant strains, thus rendering the drug worth-
less. Hepatotoxicity is common to most antifungals, and
the potential for endocrine toxicity exists, particularly at
high doses. Other considerations are the cost and cross-
reactions with other therapeutic agents (e.g., anticoagu-
lants). However, by prescribing these agents according to
their pharmacodynamic properties, one can achieve max-
imal antifungal activity while simultaneously minimizing
patient exposure. Clearly, an ideal antimycotic for the
treatment of oral candidoses is not yet available. But cer-
tain agents described above are better than others with
respect to efficacy, tolerability, patient compliance, and
cost-effectiveness. Most importantly, however, antifungal
agents, however potent, may be rendered ineffective in
the long term if the underlying predisposing factors are
not attended to in the first instance.
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